Key result
Beating-heart mitral valve replacement resulted in lower serum troponin I levels 6 hours postoperatively compared to conventional MVR.
Why the study?
Methods have been developed to overcome ischemia/reperfusion injury after cardioplegic arrest, but the safety, efficacy, and applicability of beating-heart versus conventional mitral valve replacement needed assessment.
Does beating-heart MVR improve safety and efficacy compared to conventional MVR in patients undergoing mitral valve replacement?
RCT (n=40)
randomly assigned
Does beating-heart MVR improve safety and efficacy compared to conventional MVR in patients undergoing mitral valve replacement?
Beating-heart mitral valve replacement is a safe alternative to conventional MVR, associated with lower postoperative troponin I release but a more blood-filled surgical field.
Answers are grounded in this paper and cite their sources.
Beating-heart MVR shows comparable operative times with notable conversions; leaves open routine adoption pending larger RCTs.
Background: Various methods have been developed to overcome the deleterious effects of ischemia/ reperfusion injury that occurs after cardioplegic arrest. The aim of the study was to assess the safety, efficacy, and applicability of the beating-heart mitral valve replacement (MVR) compared to the conventional MVR. Methods: Forty patients scheduled for mitral valve replacement were randomly assigned into two groups, conventional MVR as the control group (n= 20) and beating-heart MVR with continuous antegrade coronary perfusion as the study group (n=20). Three patients in the beating-heart group were converted to the conventional technique because of the blood-flooded field and excluded from the analysis. Results: The preoperative clinical and echocardiographic variables were comparable between both groups. There was no significant difference between both groups regarding cardiopulmonary bypass time (79.4± 14 vs. 75.7± 10.9 minutes; p= 0.398) and total operative time (200± 55.6 vs. 183.9± 67.5 min; p= 0.458) in the conventional and beating-heart group, respectively. Serum troponin I level was significantly higher in the conventional MVR group 6 hours postoperatively (4.9±4 vs. 2.7±1.2 ng/ml; p= 0.036), while there was no significant difference between both groups regarding total CK and CK-MB (p= 0.565 & 0.597 respectively). Eight patients (44%) in the conventional MVR group needed inotropic support compared to 3 patients (19%) in the beating-heart MVR group (P = 0.11). There was no operative mortality or major morbidity in both groups. At 6-months follow-up, there was no difference in NYHA class (1.3±0.3 vs. 1.2±0.3; p= 0.336) and the ejection fraction (60.0±6.3 vs. 63.2±6 %; p= 0.139) in the conventional vs. beating-heart group. Conclusion: Beating-heart MVR is a safe alternative to the conventional method with comparable outcomes. There is a relatively blood-filled field compared to the conventional technique.
No takes yet. Share an insight, caveat, or question.
Badr et al. (2020) conducted an RCT in Mitral valve replacement (n=40). Beating-heart mitral valve replacement vs. Conventional mitral valve replacement was evaluated on Serum troponin I level 6 hours postoperatively (ng/ml) (p=0.036). Beating-heart mitral valve replacement resulted in lower serum troponin I levels 6 hours postoperatively compared to conventional MVR.
Synapse has enriched 10 related papers. Consider them for comparative context: